TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9362179

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 1560429

Group type: EXPERIMENTAL
Intervention: Captopril, Methyldopa, Propranolol
Number of subjects: 620

Group type: COMPARATOR
Intervention: One antihypertensive medication
Number of subjects: 620
Study: 2865150

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30698629

Group type: EXPERIMENTAL
Intervention: Semiskimmed milk (1.5% fat) for 4 days
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Whole milk (3.5% fat) for 4 days
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (wash-out periods)
Number of subjects: 109
Study: 30137550

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 116
Study: 26861942

Group type: EXPERIMENTAL
Intervention: EQUIA, a new glass ionomer restoration material
Number of subjects: 323
Study: 25012072

Group type: EXPERIMENTAL
Intervention: Single psycho‐oncological therapy session
Number of subjects: 45

Group type: COMPARATOR
Intervention: Single‐session relaxation intervention
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Comparative analysis of both interventions
Number of subjects: 45
Study: 22450428

Group type: EXPERIMENTAL
Intervention: Aliskiren (150-300 mg/daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ramipril (5-10 mg/daily)
Number of subjects: 50
Study: 20116312

Group type: EXPERIMENTAL
Intervention: Single gloves
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Double gloves (outer glove)
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Double gloves (inner glove)
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Surgeons
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Assistants
Number of subjects: 1537
Study: 17139035

Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lithium monotherapy for 1 year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with psychotic features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with a greater number of previous depressive episodes
Number of subjects: 0
Study: 15107915

Group type: EXPERIMENTAL
Intervention: Zinc oxide‐eugenol cement
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 60
Study: 10958077

Group type: EXPERIMENTAL
Intervention: Oral cocaine (100 mg, p.o.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral cocaine (0 mg, 25 mg, 50 mg, 100 mg, 0 mg)
Number of subjects: 8
Study: 9078828

Group type: EXPERIMENTAL
Intervention: Early indomethacin (0.2 mg/kg intravenously at 12 postnatal hours and every 24 h for two more doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8384820

Group type: EXPERIMENTAL
Intervention: alpha 2B interferon
Number of subjects: 24
Study: 3267404

Group type: EXPERIMENTAL
Intervention: Cognitive training on spatial orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive training on inductive reasoning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive training interventions
Number of subjects: 0
Study: 31752795

Group type: EXPERIMENTAL
Intervention: Energy drinks consumption
Number of subjects: 783

Group type: COMPARATOR
Intervention: Knowledge of energy drinks
Number of subjects: 783

Group type: COMPARATOR
Intervention: Energy drinks consumption frequency
Number of subjects: 783
Study: 29595671

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (2.0 mg/kg bolus, 3.0 mg/kg/h infusion)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study: 26551637

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT) as consolidation treatment in first remission for HR(FLT3‐ITD) AML
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT) in first remission for LR(FLT3‐ITD) AML and wild-type NPM1
Number of subjects: 209

Group type: COMPARATOR
Intervention: Consolidation chemotherapy for HR(FLT3‐ITD) AML
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT) in first remission for LR(FLT3‐ITD) AML with concomitant NPM1 mutation
Number of subjects: 209
Study: 25042700

Group type: EXPERIMENTAL
Intervention: Multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic FOLFOXIRI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Systemic chemotherapy (FOLFOXIRI alone)
Number of subjects: 17
Study: 22500909

Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium (0.5 mL magnesium 10% combined with bupivacaine 15 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (0.5 mL fentanyl combined with bupivacaine 15 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (0.5 mL distilled water combined with bupivacaine 15 mg)
Number of subjects: 90
Study: 20595645

Group type: EXPERIMENTAL
Intervention: Strawberry beverage (Str; containing 10 g freeze-dried fruit)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo beverage (Pbo)
Number of subjects: 24
Study: 18006422

Group type: EXPERIMENTAL
Intervention: Educational quality improvement intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study: 16708293

Group type: EXPERIMENTAL
Intervention: Perioperative vapreotide
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 14659354

Group type: EXPERIMENTAL
Intervention: Epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8, repeated every 3 weeks
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8
Number of subjects: 99
Study: 10870037

Group type: EXPERIMENTAL
Intervention: Glucagon (GLU; 0.017 mg/kg i.m.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucagon (GLU; 0.017 mg/kg i.m.) + hCRH (2.0 µg/kg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glucagon (GLU; 0.017 mg/kg i.m.) + AVP (0.17 U/kg i.m.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: hCRH + AVP
Number of subjects: 6
Study: 9195148

Group type: EXPERIMENTAL
Intervention: Azelastine (0.56 mg bid)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Beclomethasone (0.2 mg bid)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 9114912

Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dilevalol 800 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Labetalol 200 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Labetalol 400 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3542917

Group type: EXPERIMENTAL
Intervention: Naproxen sodium therapy
Number of subjects: 45
Study: 31755993

Group type: EXPERIMENTAL
Intervention: Topical omiganan 2.5%
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study: 30394834

Group type: EXPERIMENTAL
Intervention: Tightly controlled renoprotective protocol including regular clinical evaluations, blood pressure management, and glucocorticoid dose reduction if indicated.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Tightly controlled renoprotective protocol
Number of subjects: 13
Study: 27531132

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24164309

Group type: EXPERIMENTAL
Intervention: Aloe vera gel (0.5% w/w), applied four times a day for 5 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Myrrh gel (0.5% w/w), applied four times a day for 5 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Plain mucoadhesive gel (placebo), applied four times a day for 5 days
Number of subjects: 90
Study: 22172430

Group type: EXPERIMENTAL
Intervention: 40 infusions of a multicomponent disodium EDTA chelation solution
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: Oral, high-dose multivitamin and mineral supplement
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: Quality-of-life outcomes (900-patient substudy)
Number of subjects: 1708
Study: 20797891

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (preop-RT) with chemotherapy (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative radiotherapy (preop-RT) without chemotherapy (Control)
Number of subjects: 0
Study: 18402597

Group type: EXPERIMENTAL
Intervention: Regular doses of CBM588
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Double doses of CBM588
Number of subjects: 19

Group type: COMPARATOR
Intervention: Without probiotics (Control Group A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Regular doses of CBM588 (Group B)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Double doses of CBM588 (Group C)
Number of subjects: 19
Study: 15733717

Group type: EXPERIMENTAL
Intervention: Early enteral tube feeding
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG) feeding
Number of subjects: 1180

Group type: COMPARATOR
Intervention: No tube feeding for more than 7 days
Number of subjects: 1180
Study: 12928996

Group type: EXPERIMENTAL
Intervention: Specific stabilizing exercise of the M. multifidus and M. transversus abdominis
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 99
Study: 10489788

Group type: EXPERIMENTAL
Intervention: Smoking cessation programs during pregnancy
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: High intensity smoking cessation interventions
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Validated smoking cessation interventions
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: High quality smoking cessation interventions
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Smoking relapse prevention programs
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Smoking cessation programs
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Single large cluster-randomized trial
Number of subjects: 9000
Study: 8646946

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms bolus injection)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Octreotide (10 micrograms bolus injection)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Octreotide (250 micrograms/hour infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1655867

Group type: EXPERIMENTAL
Intervention: Intraarterial Adriamycin (60 mg/m2) with lipiodol (10 ml)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intraarterial Adriamycin (60 mg/m2) without lipiodol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous Adriamycin (60 mg/m2)
Number of subjects: 16
Study: 6344591

Group type: EXPERIMENTAL
Intervention: Ascorbic acid therapy
Number of subjects: 6
Study: 31989151

Group type: EXPERIMENTAL
Intervention: roluperidone 32 mg
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: roluperidone 64 mg
Number of subjects: 244

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 244
Study: 30097364

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional formula enriched with Omega-3 fatty acids (O3FA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Preoperative balanced energy high-protein formula (Control Group)
Number of subjects: 40
Study: 28074235

Group type: EXPERIMENTAL
Intervention: Chemotherapy and CNS radiotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (newly diagnosed children)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both treated groups (chemotherapy alone and chemotherapy with CNS radiotherapy)
Number of subjects: 33
Study: 26022945

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 3 months
Number of subjects: 224

Group type: COMPARATOR
Intervention: No CPAP treatment for 3 months
Number of subjects: 224
Study: 23143842

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole 960 mg twice daily
Number of subjects: 181
Study: 22134457

Group type: EXPERIMENTAL
Intervention: Cognitive Differentiation Program in Individualized Sessions (CDi)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cognitive Differentiation Program in Group Sessions (CDg)
Number of subjects: 26
Study: 19822510

Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Number of subjects: 125

Group type: COMPARATOR
Intervention: Racemic leucovorin
Number of subjects: 125
Study: 15918064

Group type: EXPERIMENTAL
Intervention: Viscoseal (10 ml)
Number of subjects: 50
Study: 15249566

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Comparison
Number of subjects: 522
Study: 10908002

Group type: EXPERIMENTAL
Intervention: Matrix model, a manualized program of intensive outpatient treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 150
Study: 9364851

Group type: EXPERIMENTAL
Intervention: MR venography with tourniquet after leg-warming
Number of subjects: 8

Group type: COMPARATOR
Intervention: MR venography
Number of subjects: 8

Group type: COMPARATOR
Intervention: MR venography with tourniquet around the knee
Number of subjects: 8

Group type: COMPARATOR
Intervention: MR venography after leg-warming
Number of subjects: 8
Study: 8455074

Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg.kg-1 i.v. over 20 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 3778565

Group type: EXPERIMENTAL
Intervention: 60‐mg urapidil slow release‐capsule
Number of subjects: 12

Group type: COMPARATOR
Intervention: 30‐mg urapidil drinking ampoule (Ebrantil)
Number of subjects: 12
Study: 29798745

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/Piperaquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0
Study: 28062468

Group type: EXPERIMENTAL
Intervention: Self-perceived 10-year cardiovascular risk estimation using a 3-item scale (high-risk, moderate-risk, low-risk)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Underestimation of 10-year cardiovascular risk
Number of subjects: 514
Study: 25468398

Group type: EXPERIMENTAL
Intervention: Telephone motivational interviewing intervention (Beating Fatigue)
Number of subjects: 44
Study: 23359371

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 48
Study: 20800381

Group type: EXPERIMENTAL
Intervention: 0.1% mometasone furoate (MMF)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 176
Study: 18574645

Group type: EXPERIMENTAL
Intervention: Simulated IJV puncture in morbidly obese patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Simulated IJV puncture in morbidly obese patients at 60 degrees head rotation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Simulated IJV puncture in morbidly obese patients at 0 degrees head rotation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Simulated IJV puncture in morbidly obese patients at 30 degrees head rotation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simulated IJV puncture in nonobese patients
Number of subjects: 70
Study: 16583726

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 14633753

Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 33

Group type: COMPARATOR
Intervention: Lidocaine 2%
Number of subjects: 33
Study: 12422059

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-30 mg/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nortriptyline (targeted to 190-570 nmol/l)
Number of subjects: 44
Study: 9589267

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naloxone 0.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg/naloxone 0.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine 15 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8024075

Group type: EXPERIMENTAL
Intervention: Mefloquine (1,250 mg divided between two doses of 750 and 500 mg six hours apart) plus doxycycline (200 mg once a day for seven days)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Artesunate (300 mg total for 2.5 days; 100 mg followed by 50 mg every 12 hr for 2.5 days) plus doxycycline (200 mg once a day for seven days)
Number of subjects: 109
Study: 2645244

Group type: EXPERIMENTAL
Intervention: Ioversol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diatrizoate
Number of subjects: 120
Study: 30901951

Group type: EXPERIMENTAL
Intervention: Resilience training program (6 weeks, 2 times per week for 75 min)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Resilience training program
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study: 28167214

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis assisted by Doppler monitoring of blood flow (n=72)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard, visually guided endoscopic hemostasis (control, n=76)
Number of subjects: 148
Study: 25887312

Group type: EXPERIMENTAL
Intervention: Multifactorial and multidisciplinary intervention
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Multifactorial and multidisciplinary intervention in subjects with nutritional risk
Number of subjects: 328
Study: 23946124

Group type: EXPERIMENTAL
Intervention: Carers' expressed emotion and level of psychological control
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Interventions targeting interpersonal maintaining factors such as carer distress
Number of subjects: 152
Study: 21415616

Group type: EXPERIMENTAL
Intervention: Enhanced care management services pilot program
Number of subjects: 0
Study: 19622463

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m², Cyclophosphamide 1000 mg/m², Vincristine 1.4 mg/m² (max 2 mg), Prednisone 50 mg every other day for 30 days, G-CSF on days 7-10 after each cycle
Number of subjects: 10
Study: 17890860

Group type: EXPERIMENTAL
Intervention: cuprammonium membrane
Number of subjects: 14
Study: 15548216

Group type: EXPERIMENTAL
Intervention: Local anaesthetic cream (EMLA) applied for forearm skin anaesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Local anaesthetic cream (EMLA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11535502

Group type: EXPERIMENTAL
Intervention: Younger children (age not specified)
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Older children (age not specified)
Number of subjects: 698
Study: 10947374

Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discussion Group use of CHESS
Number of subjects: 0
Study: 8068212

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide and hydrocortisone
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Formestane
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus aminoglutethimide/hydrocortisone
Number of subjects: 322

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 322
Study: 30050655

Group type: EXPERIMENTAL
Intervention: Red Wine (RW)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: White Wine (WW)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vodka (VDK)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mediterranean Meal (MeDM)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: High-Fat Meal (HFM)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HFM + Red Wine (RW)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HFM + White Wine (WW)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HFM + Vodka (VDK)
Number of subjects: 54
Study: 26936358

Group type: EXPERIMENTAL
Intervention: 1200 mg/d ibuprofen (IBU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0
Study: 24734285

Group type: EXPERIMENTAL
Intervention: SQ-standardized subcutaneous immunotherapy (SCIT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy tablets (SLIT tablet)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (neither SCIT nor SLIT tablet)
Number of subjects: 40
Study: 22484377

Group type: EXPERIMENTAL
Intervention: 8% strontium acetate in silica base
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 8% arginine, calcium carbonate, 1450 ppm sodium monofluorophosphate (Colgate Sensitive Pro‐Relief(®))
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1450 ppm sodium fluoride (control paste)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 28
Study: 20110249

Group type: EXPERIMENTAL
Intervention: Cinacalcet (30‐180 mg/day) plus low‐dose active vitamin D
Number of subjects: 360

Group type: COMPARATOR
Intervention: Flexible dosing of active vitamin D alone
Number of subjects: 360
Study: 18427279

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/d
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 16005552

Group type: EXPERIMENTAL
Intervention: Combined influenza and pneumococcal vaccination
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Influenza alone
Number of subjects: 690

Group type: COMPARATOR
Intervention: Hepatitis B vaccination (control)
Number of subjects: 690
Study: 12957502

Group type: EXPERIMENTAL
Intervention: Substance P (SP) at 10(‐9) M
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Substance P (SP) at 10(‐6) M
Number of subjects: 22